Cobalamin deficiency, hyperhomocysteinemia, and dementia

Neuropsychiatric Disease and Treatment

Volumn 6, Issue 1, 2010, Pages 159-195

  Werder, Steven F ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b Community Health Center of Southeast Kansas ^*  (United States)

Author keywords

Alzheimer; B12; Cobalamin; Cognitive dysfunction; Cognitive impairment; Cyanocobalamin; Dementia; Homocysteine; Homocystinuria; Hyperhomocysteinemia

Indexed keywords

EID: 79952008609     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S6564     Document Type: Review

References (511)

1. Arnold SE, Kumar A. Reversible dementias. Med Clin North Am. 1993;77(1):215-230.
2. Practice guideline for psychiatric evaluation of adults. American Psychiatric Association. Am J Psychiatry. 1995;152(11 Suppl):63-80.
3. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1143-1153.
4. Feldman HH, Jacova C, Robillard A, et al. Diagnosis and treatment of dementia: 2. Diagnosis. CMAJ. 2008;178(7):825-836.
5. Schneede J, Ueland PM. Novel and estabslished markers of cobalamin deficiency: complementary or exclusive diagnostic strategies. Semin Vasc Med. 2005;5(2):140-155.
6. Vanderjagt DJ, McCarthy DM. Pernicious Anemia. In: Glew RH, Ninomiya Y, editors. Clinical Studies in Medical Biochemistry. 2nd Ed. New York, NY: Oxford University Press; 2006. p. 122-133.
7. Klee GG. Cobalamin and folate evaluation: measurement of methylmalonic acid and homocysteine vs vitamin B(12) and folate. Clin Chem. 2000;46(8 Pt 2):1277-1283.
8. Olivieri G, Hess C, Savaskan E, et al. Melatonin protects SHSY5Y neuroblastoma cells from cobalt-induced oxidative stress, neurotoxicity and increased beta-amyloid secretion. J Pineal Res. 2001;31(4): 320-325.
9. Allen LH. How common is vitamin B-12 deficiency? Am J Clin Nutr. 2009;89(2):693S-696S.
10. Basun H, Fratiglioni L, Winblad B. Cobalamin levels are not reduced in Alzheimer's disease: results from a population-based study. J Am Geriatr Soc. 1994;42(2):132-136.
11. Clarke R, Refsum H, Birks J, et al. Screening for vitamin B-12 and folate deficiency in older persons. Am J Clin Nutr. 2003;77(5):1241-1247.
12. Clarke R, Grimley Evans J, Schneede J, et al. Vitamin B12 and folate deficiency in later life. Age Ageing. 2004;33(1):34-41.
13. Crystal HA, Ortof E, Frishman WH, Gruber A, Hershman D, Aronson M. Serum vitamin B12 levels and incidence of dementia in a healthy elderly population: a report from the Bronx Longitudinal Aging Study. J Am Geriatr Soc. 1994;42(9):933-936.
14. Elsborg L, Hansen T, Rafaelsen OJ. Vitamin B12 concentrations in psychiatric patients. Acta Psychiatr Scand. 1979;59(2):145-152.
15. Lechner K, Fodinger M, Grisold W, Puspok A, Sillaber C. Vitamin B12 deficiency. New data on an old theme. Wien Klin Wochenschr. 2005;117(17):579-591.
16. Malouf R, Areosa Sastre A. Vitamin B12 for cognition. Cochrane Database Syst Rev. 2003(3):CD004326.
17. Refsum H, Smith AD, Ueland PM, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem. 2004;50(1):3-32.
18. Singh NN, Thomas FP, Diamond AL, Diamond R. Vitamin B-12 associated neurological diseases. 2006. Available from: http://emedicine. medscape.com/article/1152670-overview. Accessed on Nov 3, 2009.
19. Stabler SP, Lindenbaum J, Allen RH. Vitamin B-12 deficiency in the elderly: current dilemmas. Am J Clin Nutr. 1997;66(4):741-749.
20. Sumner AE, Chin MM, Abrahm JL, et al. Elevated methylmalonic acid and total homocysteine levels show high prevalence of vitamin B12 deficiency after gastric surgery. Ann Intern Med. 1996;124(5): 469-476.
21. Wolters M, Strohle A, Hahn A. Age-associated changes in the metabolism of vitamin B(12) and folic acid: prevalence, aetiopathogenesis and pathophysiological consequences. Z Gerontol Geriatr. 2004;37(2): 109-135.
22. Wolters M, Strohle A, Hahn A. Cobalamin: a critical vitamin in the elderly. Prev Med. 2004;39(6):1256-1266.
23. Worrall B, Rowland L. Nutritional disorders: Malnutrition, malabsorption, and B12 and other vitamin deficiencies. In: Rowland L, editor. Merritt's Neurology. 11th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005. p. 1091-1098.
24. Cunha UG, Rocha FL, Peixoto JM, Motta MF, Barbosa MT. Vitamin B12 deficiency and dementia. Int Psychogeriatr. 1995;7(1):85-88.
25. Karnaze DS, Carmel R. Low serum cobalamin levels in primary degenerative dementia. Do some patients harbor atypical cobalamin deficiency states? Arch Intern Med. 1987;147(3):429-431.
26. Teunisse S, Bollen AE, van Gool WA, Walstra GJ. Dementia and subnormal levels of vitamin B12: effects of replacement therapy on dementia. J Neurol. 1996;243(7):522-529.
27. Greilberger J, Koidl C, Greilberger M, et al. Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease. Free Radic Res. 2008;42(7):633-638.
28. Whyte EM, Mulsant BH, Butters MA, et al. Cognitive and behavioral correlates of low vitamin B12 levels in elderly patients with progressive dementia. Am J Geriatr Psychiatry. 2002;10(3):321-327.
29. Regland B, Gottfries CG, Oreland L. Vitamin B12-induced reduction of platelet monoamine oxidase activity in patients with dementia and pernicious anaemia. Eur Arch Psychiatry Clin Neurosci. 1991;240(4-5):288-291.
30. Bopp-Kistler I, Ruegger-Frey B, Grob D, Six P. Vitamin B12 deficiency in geriatrics. Schweiz Rundsch Med Prax. 1999;88(45): 1867-1875.
31. Butler CC, Vidal-Alaball J, Cannings-John R, et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency: a systematic review of randomized controlled trials. Fam Pract. 2006;23(3):279-285.
32. Nagga K, Rajani R, Mardh E, Borch K, Mardh S, Marcusson J. Cobalamin, folate, methylmalonic acid, homocysteine, and gastritis markers in dementia. Dement Geriatr Cogn Disord. 2003;16(4):269-275.
33. Nilsson-Ehle H. Age-related changes in cobalamin (vitamin B12) handling. Implications for therapy. Drugs Aging. 1998;12(4):277-292.
34. Vidal-Alaball J, Butler CC, Cannings-John R, et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database Syst Rev. 2005(3):CD004655.
35. Diaz-Arrastia R. Homocysteine and neurologic disease. Arch Neurol. 2000;57(10):1422-1427.
36. Brosnan JT, Brosnan ME. The sulfur-containing amino acids: an overview. J Nutr. 2006;136(6 Suppl):1636S-1640S.
37. Barone P, Burn DJ, van Laar T, Hsu C, Poewe W, Lane RM. Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. Mov Disord. 2008;23(11):1532-1540.
38. Gonzalez-Gross M, Sola R, Albers U, et al. B-vitamins and homocysteine in Spanish institutionalized elderly. Int J Vitam Nutr Res. 2007;77(1):22-33.
39. Marengoni A, Cossi S, De Martinis M, Calabrese PA, Orini S, Grassi V. Homocysteine and disability in hospitalized geriatric patients. Metabolism. 2004;53(8):1016-1020.
40. Nilsson K, Gustafson L, Hultberg B. The plasma homocysteine concentration is better than that of serum methylmalonic acid as a marker for sociopsychological performance in a psychogeriatric population. Clin Chem. 2000;46(5):691-696.
41. Ravaglia G, Forti P, Maioli F, et al. Blood homocysteine and vitamin B levels are not associated with cognitive skills in healthy normally ageing subjects. J Nutr Health Aging. 2000;4(4):218-222.
42. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338(15):1042-1050.
43. Briani C, Cagnin A, Gallo L, et al. Anti-heparan sulphate antibodies and homocysteine in dementia: markers of vascular pathology? J Neurol Sci. 2005;229-230:215-218.
44. Nilsson K, Gustafson L, Hultberg B. Plasma homocysteine is a sensitive marker for tissue deficiency of both cobalamines and folates in a psychogeriatric population. Dement Geriatr Cogn Disord. 1999;10(6):476-482.
45. Andres E, Loukili NH, Noel E, et al. Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ. 2004;171(3):251-259.
46. Bergeron C, Ranalli PJ, Miceli PN. Amyloid angiopathy in Alzheimer's disease. Can J Neurol Sci. 1987;14(4):564-569.
47. Cook S, Hess OM. Homocysteine and B vitamins. Handb Exp Pharmacol. 2005(170):325-338.
48. El Otmani H, El Moutawakil B, Moutaouakil F, Gam I, Rafai MA, Slassi I. Postoperative dementia: toxicity of nitrous oxide. Encephale. 2007;33(1):95-97.
49. El Otmani H, Moutaouakil F, Midafi N, et al. Cobalamin deficiency: Neurological aspects in 27 cases. Rev Neurol (Paris). 2009;165(3): 263-267.
50. Hadithi M, Mulder CJ, Stam F, et al. Effect of B vitamin supplementation on plasma homocysteine levels in celiac disease. World J Gastroenterol. 2009;15(8):955-960.
51. Irizarry MC, Gurol ME, Raju S, et al. Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. Neurology. 2005;65(9):1402-1408.
52. Jacobsen DW, Gatautis VJ, Green R, et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem. 1994;40(6):873-881.
53. Myles PS, Chan MT, Leslie K, Peyton P, Paech M, Forbes A. Effect of nitrous oxide on plasma homocysteine and folate in patients undergoing major surgery. Br J Anaesth. 2008;100(6):780-786.
54. O'Suilleabhain PE, Bottiglieri T, Dewey RB, Jr., Sharma S, Diaz-Arrastia R. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease. Mov Disord. 2004;19(12):1403-1408.
55. Saibeni S, Lecchi A, Meucci G, et al. Prevalence of hyperhomocysteinemia in adult gluten-sensitive enteropathy at diagnosis: role of B12, folate, and genetics. Clin Gastroenterol Hepatol. 2005;3(6): 574-580.
56. Snow CF. Laboratory diagnosis of vitamin B12 and folate deficiency: a guide for the primary care physician. Arch Intern Med. 1999;159(12):1289-1298.
57. Stabler SP, Lindenbaum J, Allen RH. The use of homocysteine and other metabolites in the specific diagnosis of vitamin B-12 deficiency. J Nutr. 1996;126(4 Suppl):1266S-1272S.
58. Weir DG, Scott JM. Brain function in the elderly: role of vitamin B12 and folate. Br Med Bull. 1999;55(3):669-682.
59. Koike T, Kuzuya M, Kanda S, et al. Raised homocysteine and low folate and vitamin B-12 concentrations predict cognitive decline in communitydwelling older Japanese adults. Clin Nutr. 2008;27(6):865-871.
60. Li L, Cao D, Desmond R, et al. Cognitive performance and plasma levels of homocysteine, vitamin B12, folate and lipids in patients with Alzheimer disease. Dement Geriatr Cogn Disord. 2008;26(4): 384-390.
61. Nilsson K, Gustafson L, Hultberg B. Plasma homocysteine levels and different forms of vascular disease in patients with dementia and other psychogeriatric diseases. Dement Geriatr Cogn Disord. 2009;27(1): 88-95.
62. Conrad ME. Pernicious anemia. Available from: http://emedicine. medscape.com/article/204930-overview. Accessed September 5, 2009.
63. Schroecksnadel K, Frick B, Winkler C, Leblhuber F, Wirleitner B, Fuchs D. Hyperhomocysteinemia and immune activation. Clin Chem Lab Med. 2003;41(11):1438-1443.
64. Schroecksnadel K, Frick B, Wirleitner B, Winkler C, Schennach H, Fuchs D. Moderate hyperhomocysteinemia and immune activation. Curr Pharm Biotechnol. 2004;5(1):107-118.
65. Lehmann J, Tsai C, Wood PL. Homocysteic acid as a putative excitatory amino acid neurotransmitter: I. Postsynaptic characteristics at N-methyl-D-aspartate-type receptors on striatal cholinergic interneurons. J Neurochem. 1988;51(6):1765-1770.
66. Lipton SA, Kim WK, Choi YB, et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A. 1997;94(11):5923-5928.
67. Bottiglieri T, Godfrey P, Flynn T, Carney MW, Toone BK, Reynolds EH. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry. 1990;53(12):1096-1098.
68. Huang RF, Huang SM, Lin BS, Wei JS, Liu TZ. Homocysteine thiolactone induces apoptotic DNA damage mediated by increased intracellular hydrogen peroxide and caspase 3 activation in HL-60 cells. Life Sci. 2001;68(25):2799-2811.
69. Kim HJ, Cho HK, Kwon YH. Synergistic induction of ER stress by homocysteine and beta-amyloid in SH-SY5Y cells. J Nutr Biochem. 2008;19(11):754-761.
70. Kruman II, Culmsee C, Chan SL, et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci. 2000;20(18):6920-6926.
71. Zou CG, Zhao YS, Gao SY, et al. Homocysteine promotes proliferation and activation of microglia. Neurobiol Aging. 2009 Jan 6 [Epub ahead of print].
72. Rabaneda LG, Carrasco M, Lopez-Toledano MA, et al. Homocysteine inhibits proliferation of neuronal precursors in the mouse adult brain by impairing the basic fibroblast growth factor signaling cascade and reducing extracellular regulated kinase 1/2-dependent cyclin E expression. FASEB J. 2008;22(11):3823-3835.
73. Kumar M, Tyagi N, Moshal KS, et al. Homocysteine decreases blood flow to the brain due to vascular resistance in carotid artery. Neurochem Int. 2008;53(6-8):214-219.
74. Kumar M, Tyagi N, Moshal KS, et al. GABAA receptor agonist mitigates homocysteine-induced cerebrovascular remodeling in knockout mice. Brain Res. 2008;1221:147-153.
75. Herrmann W, Obeid R. Biomarkers of folate and vitamin B(12) status in cerebrospinal fluid. Clin Chem Lab Med. 2007;45(12):1614-1620.
76. Kamath AF, Chauhan AK, Kisucka J, et al. Elevated levels of homocysteine compromise blood-brain barrier integrity in mice. Blood. 2006;107(2):591-593.
77. Lominadze D, Roberts AM, Tyagi N, Moshal KS, Tyagi SC. Homocysteine causes cerebrovascular leakage in mice. Am J Physiol Heart Circ Physiol. 2006;290(3):H1206-H1213.
78. Tyagi SC, Lominadze D, Roberts AM. Homocysteine in microvascular endothelial cell barrier permeability. Cell Biochem Biophys. 2005;43(1):37-44.
79. Poddar R, Sivasubramanian N, DiBello PM, Robinson K, Jacobsen DW. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: implications for vascular disease. Circulation. 2001;103(22): 2717-2723.
80. Bi XH, Zhao HL, Zhang ZX, Zhang JW. Association of RFC1 A80G and MTHFR C677T polymorphisms with Alzheimer's disease. Neurobiol Aging. 2009;30(10):1601-1607.
81. Deshmukh A, Rodrigue KM, Kennedy KM, Land S, Jacobs BS, Raz N. Synergistic effects of the MTHFR C677T polymorphism and hypertension on spatial navigation. Biol Psychol. 2008;80(2):240-245.
82. Kim JM, Stewart R, Kim SW, et al. Methylenetetrahydrofolate reductase gene and risk of Alzheimer's disease in Koreans. Int J Geriatr Psychiatry. 2008;23(5):454-459.
83. Weih M, Junge-Hulsing J, Mehraein S, Ziemer S, Einhaupl KM. Hereditary thrombophilia with ischemiC stroke and sinus thrombosis. Diagnosis, therapy and meta-analysis. Nervenarzt. 2000;71(12): 936-945.
84. Kelly PJ, Rosand J, Kistler JP, et al. Homocysteine, MTHFR 677C T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology. 2002;59(4):529-536.
85. Clarke R, Lewington S, Landray M. Homocysteine, renal function, and risk of cardiovascular disease. Kidney Int Suppl. 2003(84): S131-S133.
86. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J. 2003;146(6):948-957.
87. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet. 2005;365(9455):224-232.
88. Haywood S, Liesner R, Pindora S, Ganesan V. Thrombophilia and first arterial ischaemic stroke: a systematic review. Arch Dis Child. 2005;90(4):402-405.
89. Cronin S, Furie KL, Kelly PJ. Dose-related association of MTHFR 677T allele with risk of ischemic stroke: evidence from a cumulative meta-analysis. Stroke. 2005;36(7):1581-1587.
90. Lane R, He Y, Morris C, Leverenz JB, Emre M, Ballard C. BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Mov Disord. 2009;24(3):392-400.
91. Andres E, Kaltenbach G, Noblet-Dick M, et al. Hematological response to short-term oral cyanocobalamin therapy for the treatment of cobalamin deficiencies in elderly patients. J Nutr Health Aging. 2006;10(1):3-6.
92. Carmel R, Gott PS, Waters CH, et al. The frequently low cobalamin levels in dementia usually signify treatable metabolic, neurologic and electrophysiologic abnormalities. Eur J Haematol. 1995;54(4):245-253.
93. Karnaze DS, Carmel R. Neurologic and evoked potential abnormalities in subtle cobalamin deficiency states, including deficiency without anemia and with normal absorption of free cobalamin. Arch Neurol. 1990;47(9):1008-1012.
94. Fuso A, Cavallaro RA, Zampelli A, et al. gamma-Secretase is differentially modulated by alterations of homocysteine cycle in neuroblastoma and glioblastoma cells. J Alzheimers Dis. 2007;11(3):275-290.
95. Fuso A, Nicolia V, Cavallaro RA, et al. B-vitamin deprivation induces hyperhomocysteinemia and brain S-adenosylhomocysteine, depletes brain S-adenosylmethionine, and enhances PS1 and BACE expression and amyloid-beta deposition in mice. Mol Cell Neurosci. 2008;37(4):731-746.
96. Herrmann W. Significance of hyperhomocysteinemia. Clin Lab. 2006;52(7-8):367-374.
97. West RL, Lee JM, Maroun LE. Hypomethylation of the amyloid precursor protein gene in the brain of an Alzheimer's disease patient. J Mol Neurosci. 1995;6(2):141-146.
98. Foy CJ, Passmore AP, Vahidassr MD, Young IS, Lawson JT. Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease. QJM. 1999;92(1):39-45.
99. Harris ME, Hensley K, Butterfield DA, Leedle RA, Carney JM. Direct evidence of oxidative injury produced by the Alzheimer's beta-amyloid peptide (1-40) in cultured hippocampal neurons. Exp Neurol. 1995;131(2):193-202.
100. Nourhashemi F, Gillette-Guyonnet S, Andrieu S, et al. Alzheimer disease: protective factors. Am J Clin Nutr. 2000;71(2):643S-649S.
101. Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol. 2002;59(6):972-976.
102. Blasko I, Stampfer-Kountchev M, Robatscher P, Veerhuis R, Eikelenboom P, Grubeck-Loebenstein B. How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell. 2004;3(4):169-176.
103. Davis GK, Baboolal NS, Seales D, Ramchandani J, McKell S, McRae A. Potential biomarkers for dementia in Trinidad and Tobago. Neurosci Lett. 2007;424(1):27-30.
104. Mrak RE, Griffin WS. Potential inflammatory biomarkers in Alzheimer's disease. J Alzheimers Dis. 2005;8(4):369-375.
105. Streit WJ. Microglia and Alzheimer's disease pathogenesis. J Neurosci Res. 2004;77(1):1-8.
106. van den Kommer TN, Dik MG, Comijs HC, Jonker C, Deeg DJ. Homocysteine and inflammation: Predictors of cognitive decline in older persons? Neurobiol Aging. 2008 Nov 10. [Epub ahead of print].
107. Viel TA, Lima Caetano A, Nasello AG, et al. Increases of kinin B1 and B2 receptors binding sites after brain infusion of amyloid-beta 1-40 peptide in rats. Neurobiol Aging. 2008;29(12):1805-1814.
108. Frick B, Gruber B, Schroecksnadel K, Leblhuber F, Fuchs D. Homocysteine but not neopterin declines in demented patients on B vitamins. J Neural Transm. 2006;113(11):1815-1819.
109. Teunissen CE, Lutjohann D, von Bergmann K, et al. Combination of serum markers related to several mechanisms in Alzheimer's disease. Neurobiol Aging. 2003;24(7):893-902.
110. Teunissen CE, van Boxtel MP, Bosma H, et al. Serum markers in relation to cognitive functioning in an aging population: results of the Maastricht Aging Study (MAAS). Tijdschr Gerontol Geriatr. 2003;34(1):6-12.
111. Van Dam F, Van Gool WA. Hyperhomocysteinemia and Alzheimer's disease: A systematic review. Arch Gerontol Geriatr. 2009;48(3): 425-430.
112. Davis SR, Quinlivan EP, Shelnutt KP, et al. Homocysteine synthesis is elevated but total remethylation is unchanged by the methylenetetrahydrofolate reductase 677C T polymorphism and by dietary folate restriction in young women. J Nutr. 2005;135(5):1045-1050.
113. De La Haba G, Cantoni G. The enzymatic synthesis of S-adenosyl-L-homocysteine from adenosine and homocysteine. J Biol Chem. 1959;234(3):603-608.
114. Garcia A, Zanibbi K. Homocysteine and cognitive function in elderly people. CMAJ. 2004;171(8):897-904.
115. Tchantchou F, Graves M, Falcone D, Shea TB. S-adenosylmethionine mediates glutathione efficacy by increasing glutathione S-transferase activity: implications for S-adenosyl methionine as a neuroprotective dietary supplement. J Alzheimers Dis. 2008;14(3):323-328.
116. Gibson GE, Sheu KF, Blass JP. Abnormalities of mitochondrial enzymes in Alzheimer disease. J Neural Transm. 1998;105(8-9): 855-870.
117. Markesbery WR. The role of oxidative stress in Alzheimer disease. Arch Neurol. 1999;56(12):1449-1452.
118. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol. 2003;552(Pt 2):335-344.
119. Toohey JI. Mercaptopropionaldehyde from homocysteine: implications for Alzheimer's disease. J Alzheimers Dis. 2007;12(3):241-243.
120. McCaddon A, Hudson PR. Alzheimer's disease, oxidative stress and B-vitamin depletion. Future Neurology. 2007;2(5):537-547.
121. Serot JM, Bene MC, Faure GC. Comparative immunohistochemical characteristics of human choroid plexus in vascular and Alzheimer's dementia. Hum Pathol. 1994;25(11):1185-1190.
122. Serot JM, Christmann D, Dubost T, Bene MC, Faure GC. CSF-folate levels are decreased in late-onset AD patients. J Neural Transm. 2001;108(1):93-99.
123. Serot JM, Bene MC, Faure GC. Choroid plexus, aging of the brain, and Alzheimer's disease. Front Biosci. 2003;8:s515-s521.
124. Nijst TQ, Wevers RA, Schoonderwaldt HC, Hommes OR, de Haan AF. Vitamin B12 and folate concentrations in serum and cerebrospinal fluid of neurological patients with special reference to multiple sclerosis and dementia. J Neurol Neurosurg Psychiatry. 1990;53(11):951-954.
125. Spector R, Cancilla P, Damasio A. Is idiopathic dementia a regional vitamin deficiency state? Med Hypotheses. 1979;5(7):763-767.
126. Crossgrove JS, Li GJ, Zheng W. The choroid plexus removes betaamyloid from brain cerebrospinal fluid. Exp Biol Med (Maywood). 2005;230(10):771-776.
127. Johanson CE, Duncan JA 3rd, Klinge PM, Brinker T, Stopa EG, Silverberg GD. Multiplicity of cerebrospinal fluid functions: new challenges in health and disease. Cerebrospinal Fluid Res. 2008; 5(1):10.
128. Sontag E, Nunbhakdi-Craig V, Sontag JM, et al. Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. J Neurosci. 2007;27(11): 2751-2759.
129. Chan AY, Alsaraby A, Shea TB. Folate deprivation increases tau phosphorylation by homocysteine-induced calcium influx and by inhibition of phosphatase activity: Alleviation by S-adenosyl methionine. Brain Res. 2008;1199:133-137.
130. Luo Y, Zhou X, Yang X, Wang J. Homocysteine induces tau hyperphosphorylation in rats. Neuroreport. 2007;18(18):2005-2008.
131. Obeid R, Kasoha M, Knapp JP, et al. Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem. 2007;53(6):1129-1136.
132. Zhang CE, Tian Q, Wei W, et al. Homocysteine induces tau phosphorylation by inactivating protein phosphatase 2A in rat hippocampus. Neurobiol Aging. 2008;29(11):1654-1665.
133. Agnati LF, Genedani S, Leo G, et al. Abeta peptides as one of the crucial volume transmission signals in the trophic units and their interactions with homocysteine. Physiological implications and relevance for Alzheimer's disease. J Neural Transm. 2007;114(1):21-31.
134. Pacheco-Quinto J, Rodriguez de Turco EB, DeRosa S, et al. Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid beta peptide levels. Neurobiol Dis. 2006;22(3):651-656.
135. Viswanathan A, Raj S, Greenberg SM, et al. Plasma Abeta, homocysteine, and cognition: the Vitamin Intervention for Stroke Prevention (VISP) trial. Neurology. 2009;72(3):268-272.
136. Blasko I, Jellinger K, Kemmler G, et al. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol Aging. 2008;29(1):1-11.
137. Kang J, Park EJ, Jou I, Kim JH, Joe EH. Reactive oxygen species mediate A beta(25-35)-induced activation of BV-2 microglia. Neuroreport. 2001;12(7):1449-1452.
138. Wang JY, Wen LL, Huang YN, Chen YT, Ku MC. Dual effects of antioxidants in neurodegeneration: direct neuroprotection against oxidative stress and indirect protection via suppression of glia-mediated inflammation. Curr Pharm Des. 2006;12(27):3521-3533.
139. Harman D. Alzheimer's disease: role of aging in pathogenesis. Ann N Y Acad Sci. 2002;959:384-395; discussion 463-385.
140. Hwang J, Zheng LT, Ock J, Lee MG, Suk K. Anti-inflammatory effects of m-chlorophenylpiperazine in brain glia cells. Int Immunopharmacol. 2008;8(12):1686-1694.
141. Liu B, Gao HM, Wang JY, Jeohn GH, Cooper CL, Hong JS. Role of nitric oxide in inflammation-mediated neurodegeneration. Ann N Y Acad Sci. 2002;962:318-331.
142. Schroecksnadel K, Leblhuber F, Frick B, Wirleitner B, Fuchs D. Association of hyperhomocysteinemia in Alzheimer disease with elevated neopterin levels. Alzheimer Dis Assoc Disord. 2004;18(3):129-133.
143. Wilkinson BL, Landreth GE. The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. J Neuroinflammation. 2006;3:30.
144. Yamasaki R, Zhang J, Koshiishi I, et al. Involvement of lysosomal storage-induced p38 MAP kinase activation in the overproduction of nitric oxide by microglia in cathepsin D-deficient mice. Mol Cell Neurosci. 2007;35(4):573-584.
145. Koseoglu E, Karaman Y. Relations between homocysteine, folate and vitamin B12 in vascular dementia and in Alzheimer disease. Clin Biochem. 2007;40(12):859-863.
146. McCaddon A, Regland B, Hudson P, Davies G. Functional vitamin B(12) def iciency and Alzheimer disease. Neurology. 2002;58(9):1395-1399.
147. Shea TB. Effects of dietary supplementation with N-acetyl cysteine, acetyl-L-carnitine and S-adenosyl methionine on cognitive performance and aggression in normal mice and mice expressing human ApoE4. Neuromolecular Med. 2007;9(3):264-269.
148. Dawson H, Collins G, Pyle R, Deep-Dixit V, Taub DD. The immunoregulatory effects of homocysteine and its intermediates on T-lymphocyte function. Mech Ageing Dev. 2004;125(2):107-110.
149. Siow YL, Au-Yeung KK, Woo CW, O K. Homocysteine stimulates phosphorylation of NADPH oxidase p47phox and p67phox subunits in monocytes via protein kinase Cbeta activation. Biochem J. 2006;398(1):73-82.
150. Wang G, O K. Homocysteine stimulates the expression of monocyte chemoattractant protein-1 receptor (CCR2) in human monocytes: possible involvement of oxygen free radicals. Biochem J. 2001;357(Pt 1): 233-240.
151. Widner B, Enzinger C, Laich A, Wirleitner B, Fuchs D. Hyperhomocysteinemia, pteridines and oxidative stress. Curr Drug Metab. 2002;3(2):225-232.
152. Widner B, Leblhuber F, Frick B, Laich A, Artner-Dworzak E, Fuchs D. Moderate hyperhomocysteinaemia and immune activation in Parkinson's disease. J Neural Transm. 2002;109(12): 1445-1452.
153. Guidi I, Galimberti D, Lonati S, et al. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2006;27(2):262-269.
154. Ho PI, Collins SC, Dhitavat S, et al. Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. J Neurochem. 2001;78(2):249-253.
155. White AR, Huang X, Jobling MF, et al. Homocysteine potentiates copper-and amyloid beta peptide-mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's-type neurodegenerative pathways. J Neurochem. 2001;76(5):1509-1520.
156. Fuchs D, Jaeger M, Widner B, Wirleitner B, Artner-Dworzak E, Leblhuber F. Is hyperhomocysteinemia due to the oxidative depletion of folate rather than to insufficient dietary intake? Clin Chem Lab Med. 2001;39(8):691-694.
157. Fuso A, Seminara L, Cavallaro RA, D'Anselmi F, Scarpa S. S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci. 2005;28(1): 195-204.
158. Jin Y, Brennan L. Effects of homocysteine on metabolic pathways in cultured astrocytes. Neurochem Int. 2008;52(8):1410-1415.
159. Perry G, Cash AD, Smith MA. Alzheimer Disease and Oxidative Stress. J Biomed Biotechnol. 2002;2(3):120-123.
160. Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci. 2001;21(12):4183-4187.
161. Pratico D, Sung S. Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. J Alzheimers Dis. 2004;6(2):171-175.
162. Swerdlow RH, Khan SM. A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med Hypotheses. 2004; 63(1):8-20.
163. Dias-Santagata D, Fulga TA, Duttaroy A, Feany MB. Oxidative stress mediates tau-induced neurodegeneration in Drosophila. J Clin Invest. 2007;117(1):236-245.
164. Gamblin TC, King ME, Kuret J, Berry RW, Binder LI. Oxidative regulation of fatty acid-induced tau polymerization. Biochemistry. 2000;39(46):14203-14210.
165. Liu Q, Smith MA, Avila J, et al. Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. Free Radic Biol Med. 2005;38(6):746-754.
166. Percy M, Moalem S, Garcia A, et al. Involvement of ApoE E4 and H63D in sporadic Alzheimer's disease in a folate-supplemented Ontario population. J Alzheimers Dis. 2008;14(1):69-84.
167. Leo G, Genedani S, Filaferro M, et al. Hyper-homocysteinemia alters amyloid peptide-clusterin interactions and neuroglial network morphology and function in the caudate after intrastriatal injection of amyloid peptides. Curr Alzheimer Res. 2007;4(3): 305-313.
168. Akama KT, Albanese C, Pestell RG, Van Eldik LJ. Amyloid betapeptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism. Proc Natl Acad Sci U S A. 1998;95(10):5795-5800.
169. Butterfield DA, Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med. 2002;32(11):1050-1060.
170. Cente M, Filipcik P, Pevalova M, Novak M. Expression of a truncated tau protein induces oxidative stress in a rodent model of tauopathy. Eur J Neurosci. 2006;24(4):1085-1090.
171. Scalabrino G, Veber D, Mutti E. Experimental and clinical evidence of the role of cytokines and growth factors in the pathogenesis of acquired cobalamin-deficient leukoneuropathy. Brain Res Rev. 2008;59(1):42-54.
172. Buccellato FR, Miloso M, Braga M, et al. Myelinolytic lesions in spinal cord of cobalamin-deficient rats are TNF-alpha-mediated. FASEB J. 1999;13(2):297-304.
173. Peracchi M, Bamonti Catena F, Pomati M, De Franceschi M, Scalabrino G. Human cobalamin deficiency: alterations in serum tumour necrosis factor-alpha and epidermal growth factor. Eur J Haematol. 2001;67(2):123-127.
174. Scalabrino G. Cobalamin (vitamin B(12) in subacute combined degeneration and beyond: traditional interpretations and novel theories. Exp Neurol. 2005;192(2):463-479.
175. Scalabrino G, Veber D, Mutti E. New pathogenesis of the cobalamindeficient neuropathy. Med Secoli. 2007;19(1):9-18.
176. Scalabrino G. The multi-faceted basis of vitamin B12 (cobalamin) neurotrophism in adult central nervous system: Lessons learned from its deficiency. Prog Neurobiol. 2009;88(3):203-220.
177. Scalabrino G, Carpo M, Bamonti F, et al. High tumor necrosis factoralpha [corrected] levels in cerebrospinal fluid of cobalamin-deficient patients. Ann Neurol. 2004;56(6):886-890.
178. Scalabrino G, Peracchi M. New insights into the pathophysiology of cobalamin deficiency. Trends Mol Med. 2006;12(6):247-254.
179. Dogan M, Ozdemir O, Sal EA, et al. Psychotic disorder and extrapyramidal symptoms associated with vitamin B12 and folate deficiency. J Trop Pediatr. 2009;55(3):205-207.
180. Healton EB, Savage DG, Brust JC, Garrett TJ, Lindenbaum J. Neurologic aspects of cobalamin deficiency. Medicine (Baltimore). 1991;70(4):229-245.
181. Durand C, Mary S, Brazo P, Dollfus S. Psychiatric manifestations of vitamin B12 deficiency: a case report. Encephale. 2003;29(6): 560-565.
182. Ko SM, Liu TC. Psychiatric syndromes in pernicious anaemia-a case report. Singapore Med J. 1992;33(1):92-94.
183. Lassen E, Ewald H. Acute organic psychosis caused by thyrotoxicosis and vitamin B12 def iciency: case report. J Clin Psychiatry. 1985;46(3):106-107.
184. Evans DL, Edelsohn GA, Golden RN. Organic psychosis without anemia or spinal cord symptoms in patients with vitamin B12 deficiency. Am J Psychiatry. 1983;140(2):218-221.
185. Bolaman Z, Kadikoylu G, Yukselen V, Yavasoglu I, Barutca S, Senturk T. Oral versus intramuscular cobalamin treatment in megaloblastic anemia: a single-center, prospective, randomized, open-label study. Clin Ther. 2003;25(12):3124-3134.
186. Cubero L, Mayor J, Almirall P, Valdes M. Memory disorders in the epidemic neuropathy. Rev Neurol. 1999;28(4):343-348.
187. Kwok T, Lee J, Lam L, Woo J. Vitamin B(12) supplementation did not improve cognition but reduced delirium in demented patients with vitamin B(12) deficiency. Arch Gerontol Geriatr. 2008;46(3):273-282.
188. Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med. 1988;318(26):1720-1728.
189. Heok KE, Ho R. The many faces of geriatric depression. Curr Opin Psychiatry. 2008;21(6):540-545.
190. Saracaceanu E, Tramoni AV, Henry JM. An association between subcortical dementia and pernicious anemia-a psychiatric mask. Compr Psychiatry. 1997;38(6):349-351.
191. Goggans FC. A case of mania secondary to vitamin B12 deficiency. Am J Psychiatry. 1984;141(2):300-301.
192. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry. 2000;69(2): 228-232.
193. Meeks TW, Ropacki SA, Jeste DV. The neurobiology of neuropsychiatric syndromes in dementia. Curr Opin Psychiatry. 2006;19(6): 581-586.
194. Reif A, Pfuhlmann B, Lesch KP. Homocysteinemia as well as methylenetetrahydrofolate reductase polymorphism are associated with affective psychoses. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(7):1162-1168.
195. Dittmann S, Seemuller F, Schwarz MJ, et al. Association of cognitive deficits with elevated homocysteine levels in euthymic bipolar patients and its impact on psychosocial functioning: preliminary results. Bipolar Disord. 2007;9(1-2):63-70.
196. Dittmann S, Seemuller F, Grunze HC, et al. The impact of homocysteine levels on cognition in euthymic bipolar patients: A cross-sectional study. J Clin Psychiatry. 2008:e1-e8.
197. Osher Y, Bersudsky Y, Silver H, Sela BA, Belmaker RH. Neuropsychological correlates of homocysteine levels in euthymic bipolar patients. J Affect Disord. 2008;105(1-3):229-233.
198. Levine J, Stahl Z, Sela BA, et al. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry. 2006;60(3):265-269.
199. Kalita J, Misra UK. Vitamin B12 deficiency neurological syndromes: correlation of clinical, MRI and cognitive evoked potential. J Neurol. 2008;255(3):353-359.
200. Goldman L AA, editor. Cecil Textbook of Medicine. 22nd ed. Philadelphia, PA: Saunders, Elsevier, Inc; 2004.
201. Toh BH, van Driel IR, Gleeson PA. Pernicious anemia. N Engl J Med. 1997;337(20):1441-1448.
202. Puntambekar P, Basha MM, Zak IT, Madhavan R. Rare sensory and autonomic disturbances associated with vitamin B12 deficiency. J Neurol Sci. 2009;287(1-2):285-287.
203. Ropper A, Brown R. Diseases of the nervous system due to nutritional deficiency. In: Ropper A, Brown R, editors. Adams and Victor's Principles of Neurology. 8th ed. New York, NY:. cGraw-Hill; 2005. p. 983-1003.
204. Huckman MS, Fox J, Topel J. The validity of criteria for the evaluation of cerebral atrophy by computed tomography. Radiology. 1975;116(1):85-92.
205. de Leon MJ, George AE, Reisberg B, et al. Alzheimer's disease: longitudinal CT studies of ventricular change. AJR Am J Roentgenol. 1989;152(6):1257-1262.
206. Takeda S, Matsuzawa T. Age-related brain atrophy: a study with computed tomography. J Gerontol. 1985;40(2):159-163.
207. LeMay M. Radiologic changes of the aging brain and skull. AJR Am J Roentgenol. 1984;143(2):383-389.
208. Ito M, Hatazawa J, Yamaura H, Matsuzawa T. Age-related brain atrophy and mental deterioration-a study with computed tomography. Br J Radiol. 1981;54(641):384-390.
209. Creasey H, Schwartz M, Frederickson H, Haxby JV, Rapoport SI. Quantitative computed tomography in dementia of the Alzheimer type. Neurology. 1986;36(12):1563-1568.
210. DeCarli C, Kaye JA, Horwitz B, Rapoport SI. Critical analysis of the use of computer-assisted transverse axial tomography to study human brain in aging and dementia of the Alzheimer type. Neurology. 1990;40(6):872-883.
211. DeCarli C, Murphy DG, McIntosh AR, Teichberg D, Schapiro MB, Horwitz B. Discriminant analysis of MRI measures as a method to determine the presence of dementia of the Alzheimer type. Psychiatry Res. 1995;57(2):119-130.
212. Frisoni GB, Beltramello A, Weiss C, Geroldi C, Bianchetti A, Trabucchi M. Linear measures of atrophy in mild Alzheimer disease. AJNR Am J Neuroradiol. 1996;17(5):913-923.
213. Horn R, Ostertun B, Fric M, Solymosi L, Steudel A, Moller HJ. Atrophy of hippocampus in patients with Alzheimer's disease and other diseases with memory impairment. Dementia. 1996;7(4):182-186.
214. Jobst KA, Smith AD, Szatmari M, et al. Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet. 1992;340(8829):1179-1183.
215. Kawamura J, Meyer JS, Ichijo M, Kobari M, Terayama Y, Weathers S. Correlations of leuko-araiosis with cerebral atrophy and perfusion in elderly normal subjects and demented patients. J Neurol Neurosurg Psychiatry. 1993;56(2):182-187.
216. Luxenberg JS, Friedland RP, Rapoport SI. Quantitative X-ray computed tomography (CT) in dementia of the Alzheimer type (DAT). Can J Neurol Sci. 1986;13(4 Suppl):570-572.
217. Philpot M, Burns A. Jobst et al. Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Br J Psychiatry. 1993;163:809-812.
218. Whitehouse PJ. Clinical Practice Guidelines: Guidelines Abstracted from the American Academy of Neurology's Dementia Guidelines for Early Detection, Diagnosis, and Management of Dementia. The American Geriatrics Society. 2008. Available from: http://www. americangeriatrics.org/products/positionpapers/aan_dementia.shtml. Accessed on August 21, 2009.
219. Burns A, Jacoby R, Levy R. Computed tomography in Alzheimer's disease: a longitudinal study. Biol Psychiatry. 1991;29(4):383-390.
220. Bertsch T, Mielke O, Holy S, et al. Homocysteine in cerebrovascular disease: an independent risk factor for subcortical vascular encephalopathy. Clin Chem Lab Med. 2001;39(8):721-724.
221. Censori B, Partziguian T, Manara O, Poloni M. Plasma homocysteine and severe white matter disease. Neurol Sci. 2007;28(5):259-263.
222. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol. 1998;55(11):1449-1455.
223. Evers S, Koch HG, Grotemeyer KH, Lange B, Deufel T, Ringelstein EB. Features, symptoms, and neurophysiological findings in stroke associated with hyperhomocysteinemia. Arch Neurol. 1997;54(10):1276-1282.
224. Hassan A, Hunt BJ, O'Sullivan M, et al. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain. 2004;127(Pt 1):212-219.
225. Hogervorst E, Ribeiro HM, Molyneux A, Budge M, Smith AD. Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Arch Neurol. 2002;59(5):787-793.
226. Naka H, Nomura E, Takahashi T, et al. Plasma total homocysteine levels are associated with advanced leukoaraiosis but not with asymptomatic microbleeds on T2*-weighted MRI in patients with stroke. Eur J Neurol. 2006;13(3):261-265.
227. Quadri P, Fragiacomo C, Pezzati R, et al. Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am J Clin Nutr. 2004;80(1):114-122.
228. Sachdev P, Parslow R, Salonikas C, et al. Homocysteine and the brain in midadult life: evidence for an increased risk of leukoaraiosis in men. Arch Neurol. 2004;61(9):1369-1376.
229. Sachdev PS. Homocysteine and brain atrophy. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(7):1152-1161.
230. Schwartz GL, Bailey KR, Mosley T, et al. Association of ambulatory blood pressure with ischemic brain injury. Hypertension. 2007;49(6):1228-1234.
231. Scott TM, Tucker KL, Bhadelia A, et al. Homocysteine and B vitamins relate to brain volume and white-matter changes in geriatric patients with psychiatric disorders. Am J Geriatr Psychiatry. 2004;12(6):631-638.
232. Seshadri S, Wolf PA, Beiser AS, et al. Association of plasma total homocysteine levels with subclinical brain injury: cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. Arch Neurol. 2008;65(5):642-649.
233. Smith AD. The worldwide challenge of the dementias: a role for B vitamins and homocysteine? Food Nutr Bull. 2008;29(2 Suppl): S143-S172.
234. Vogiatzoglou A, Refsum H, Johnston C, et al. Vitamin B12 status and rate of brain volume loss in community-dwelling elderly. Neurology. 2008;71(11):826-832.
235. Williams JH, Pereira EA, Budge MM, Bradley KM. Minimal hippocampal width relates to plasma homocysteine in community-dwelling older people. Age Ageing. 2002;31(6):440-444.
236. Wright CB, Paik MC, Brown TR, et al. Total homocysteine is associated with white matter hyperintensity volume: the Northern Manhattan Study. Stroke. 2005;36(6):1207-1211.
237. Yang LK, Wong KC, Wu MY, Liao SL, Kuo CS, Huang RF. Correlations between folate, B12, homocysteine levels, and radiological markers of neuropathology in elderly post-stroke patients. J Am Coll Nutr. 2007;26(3):272-278.
238. Jimenez I, Agulla J, Pouso M, et al. Cognitive impairment associated to leukoaraiosis: its pathophysiology, clinical manifestations and treatment. Rev Neurol. 2008;47(10):536-544.
239. Fu JH, Lu CZ, Hong Z, Dong Q, Luo Y, Wong KS. Extent of white matter lesions is related to acute subcortical infarcts and predicts further stroke risk in patients with first ever ischaemic stroke. J Neurol Neurosurg Psychiatry. 2005;76(6):793-796.
240. Longstreth WT Jr, Manolio TA, Arnold A, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke. 1996;27(8):1274-1282.
241. Streifler JY, Eliasziw M, Benavente OR, et al. Prognostic importance of leukoaraiosis in patients with symptomatic internal carotid artery stenosis. Stroke. 2002;33(6):1651-1655.
242. Streifler JY, Eliasziw M, Benavente OR, et al. Development and progression of leukoaraiosis in patients with brain ischemia and carotid artery disease. Stroke. 2003;34(8):1913-1916.
243. George AE, de Leon MJ, Gentes CI, et al. Leukoencephalopathy in normal and pathologic aging: 1. CT of brain lucencies. AJNR Am J Neuroradiol. 1986;7(4):561-566.
244. Basile AM, Pantoni L, Pracucci G, et al. Age, hypertension, and lacunar stroke are the major determinants of the severity of age-related white matter changes. The LADIS (Leukoaraiosis and Disability in the Elderly) Study. Cerebrovasc Dis. 2006;21(5-6):315-322.
245. Bastos-Leite AJ, Kuijer JP, Rombouts SA, et al. Cerebral blood flow by using pulsed arterial spin-labeling in elderly subjects with white matter hyperintensities. AJNR Am J Neuroradiol. 2008;29(7):1296-1301.
246. Farrall AJ, Wardlaw JM. Blood-brain barrier: Ageing and microvascular disease-systematic review and meta-analysis. Neurobiol Aging. 2009;30(3):337-352.
247. Schwartz GL, Fornage M, Mosley T, Turner ST. Treatment of leukoaraiosis. Curr Treat Options Cardiovasc Med. 2005;7(3):173-177.
248. Roman GC. Senile dementia of the Binswanger type. A vascular form of dementia in the elderly. JAMA. 1987;258(13):1782-1788.
249. de Lau LM, Refsum H, Smith AD, Johnston C, Breteler MM. Plasma folate concentration and cognitive performance: Rotterdam Scan Study. Am J Clin Nutr. 2007;86(3):728-734.
250. de Lau LM, Smith AD, Refsum H, Johnston C, Breteler MM. Plasma vitamin B12 status and cerebral white-matter lesions. J Neurol Neurosurg Psychiatry. 2009;80(2):149-157.
251. Inzitari D, Simoni M, Pracucci G, et al. Risk of rapid global functional decline in elderly patients with severe cerebral age-related white matter changes: the LADIS study. Arch Intern Med. 2007;167(1):81-88.
252. Dufouil C, Alperovitch A, Ducros V, Tzourio C. Homocysteine, white matter hyperintensities, and cognition in healthy elderly people. Ann Neurol. 2003;53(2):214-221.
253. Polyak Z, Stern F, Berner YN, et al. Hyperhomocysteinemia and vitamin score: correlations with silent brain ischemic lesions and brain atrophy. Dement Geriatr Cogn Disord. 2003;16(1):39-45.
254. Stenset V, Hofoss D, Johnsen L, et al. White matter lesion severity is associated with reduced cognitive performances in patients with normal CSF Abeta42 levels. Acta Neurol Scand. 2008;118(6): 373-378.
255. Wong A, Mok V, Fan YH, Lam WW, Liang KS, Wong KS. Hyperhomocysteinemia is associated with volumetric white matter change in patients with small vessel disease. J Neurol. 2006;253(4): 441-447.
256. Wallin A, Sjogren M. Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia. Mech Ageing Dev. 2001;122(16):1937-1949.
257. Babiloni C, Bosco P, Ghidoni R, et al. Homocysteine and electroencephalographic rhythms in Alzheimer disease: a multicentric study. Neuroscience. 2007;145(3):942-954.
258. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346(7):476-483.
259. Miller JW, Green R, Mungas DM, Reed BR, Jagust WJ. Homocysteine, vitamin B6, and vascular disease in AD patients. Neurology. 2002;58(10):1471-1475.
260. Ando S, Nakayama H. Cerebral amyloid angiopathy in Alzheimer's disease: with special reference to its incidence and distribution. No To Shinkei. 1984;36(11):1109-1116.
261. Coria F, Castano E, Prelli F, et al. Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis. Lab Invest. 1988;58(4):454-458.
262. Buee L, Hof PR, Bouras C, et al. Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathol (Berl). 1994;87(5):469-480.
263. Eberling JL, Jagust WJ, Reed BR, Baker MG. Reduced temporal lobe blood flow in Alzheimer's disease. Neurobiol Aging. 1992;13(4): 483-491.
264. Jobst KA, Smith AD, Barker CS, et al. Association of atrophy of the medial temporal lobe with reduced blood flow in the posterior parietotemporal cortex in patients with a clinical and pathological diagnosis of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1992;55(3):190-194.
265. Purandare N, Burns A, Daly KJ, et al. Cerebral emboli as a potential cause of Alzheimer's disease and vascular dementia: case-control study. BMJ. 2006;332(7550):1119-1124.
266. Purandare N, Voshaar RC, Morris J, et al. Asymptomatic spontaneous cerebral emboli predict cognitive and functional decline in dementia. Biol Psychiatry. 2007;62(4):339-344.
267. Agnati LF, Genedani S, Rasio G, et al. Studies on homocysteine plasma levels in Alzheimer's patients. Relevance for neurodegeneration. J Neural Transm. 2005;112(1):163-169.
268. Lee ES, Chen H, Soliman KF, Charlton CG. Effects of homocysteine on the dopaminergic system and behavior in rodents. Neurotoxicology. 2005;26(3):361-371.
269. Choi BH, Kim RC, Vaughan PJ, et al. Decreases in protease nexins in Alzheimer's disease brain. Neurobiol Aging. 1995;16(4):557-562.
270. Hanyu H, Asano T, Tanaka Y, Iwamoto T, Takasaki M, Abe K. Increased blood-brain barrier permeability in white matter lesions of Binswanger's disease evaluated by contrast-enhanced MRI. Dement Geriatr Cogn Disord. 2002;14(1):1-6.
271. Arshavsky YI. Alzheimer's disease, brain immune privilege and memory: a hypothesis. J Neural Transm. 2006;113(11):1697-1707.
272. D'Andrea MR. Add Alzheimer's disease to the list of autoimmune diseases. Med Hypotheses. 2005;64(3):458-463.
273. Groppa SA, Chekhonin VP. Specific brain antigens as the indicators of the blood-brain barrier permeability in Alzheimer's disease. Zh Nevropatol Psikhiatr Im S S Korsakova. 1991;91(9):50-52.
274. Homocysteine and risk of ischemic heart disease and stroke: a metaanalysis. JAMA. 2002;288(16):2015-2022.
275. Bautista LE, Arenas IA, Penuela A, Martinez LX. Total plasma homocysteine level and risk of cardiovascular disease: a metaanalysis of prospective cohort studies. J Clin Epidemiol. 2002;55(9): 882-887.
276. Liu XQ, Jiang P, Huang H, Yan Y. Plasma levels of endogenous hydrogen sulfide and homocysteine in patients with Alzheimer's disease and vascular dementia and the significance thereof. Zhonghua Yi Xue Za Zhi. 2008;88(32):2246-2249.
277. Moller J, Nielsen GM, Tvedegaard KC, Andersen NT, Jorgensen PE. A meta-analysis of cerebrovascular disease and hyperhomocysteinaemia. Scand J Clin Lab Invest. 2000;60(6):491-499.
278. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002; 325(7374):1202.
279. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995;274(13):1049-1057.
280. Troen AM, Shea-Budgell M, Shukitt-Hale B, Smith DE, Selhub J, Rosenberg IH. B-vitamin deficiency causes hyperhomocysteinemia and vascular cognitive impairment in mice. Proc Natl Acad Sci U S A. 2008;105(34):12474-12479.
281. Yao H, Sadoshima S, Kuwabara Y, Ichiya Y, Fujishima M. Cerebral blood flow and oxygen metabolism in patients with vascular dementia of the Binswanger type. Stroke. 1990;21(12):1694-1699.
282. Picardi A, Navajas F, Spoto S, Palma Modoni A, De Galasso L, Costantino S. A 74-year-old woman with macrocytic anemia. Clin Ter. 2002;153(1):65-67.
283. Chin AV, Robinson DJ, O'Connell H, et al. Vascular biomarkers of cognitive performance in a community-based elderly population: the Dublin Healthy Ageing study. Age Ageing. 2008;37(5): 559-564.
284. Sala I, Belen Sanchez-Saudinos M, Molina-Porcel L, et al. Homocysteine and cognitive impairment. Relation with diagnosis and neuropsychological performance. Dement Geriatr Cogn Disord. 2008;26(6):506-512.
285. Selhub J, Morris MS, Jacques PF, Rosenberg IH. Folate-vitamin B-12 interaction in relation to cognitive impairment, anemia, and biochemical indicators of vitamin B-12 deficiency. Am J Clin Nutr. 2009;89(2):702S-706S.
286. Stewart R, Asonganyi B, Sherwood R. Plasma homocysteine and cognitive impairment in an older British African-Caribbean population. J Am Geriatr Soc. 2002;50(7):1227-1232.
287. Ravaglia G, Forti P, Maioli F, et al. Homocysteine and cognitive function in healthy elderly community dwellers in Italy. Am J Clin Nutr. 2003;77(3):668-673.
288. Prins ND, Den Heijer T, Hofman A, et al. Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study. Neurology. 2002;59(9):1375-1380.
289. Cole MG, Prchal JF. Low serum vitamin B12 in Alzheimer-type dementia. Age Ageing. 1984;13(2):101-105.
290. Malaguarnera M, Ferri R, Bella R, Alagona G, Carnemolla A, Pennisi G. Homocysteine, vitamin B12 and folate in vascular dementia and in Alzheimer disease. Clin Chem Lab Med. 2004;42(9):1032-1035.
291. McCaddon A, Davies G, Hudson P, Tandy S, Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry. 1998;13(4):235-239.
292. Hagnelius NO, Wahlund LO, Nilsson TK. CSF/serum folate gradient: physiology and determinants with special reference to dementia. Dement Geriatr Cogn Disord. 2008;25(6):516-523.
293. Zoccolella S, Lamberti P, Iliceto G, et al. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions. Clin Chem Lab Med. 2005;43(10):1107-1110.
294. Ozer F, Meral H, Hanoglu L, et al. Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations. Neurol Res. 2006;28(8):853-858.
295. Budge MM, de Jager C, Hogervorst E, Smith AD. Total plasma homocysteine, age, systolic blood pressure, and cognitive performance in older people. J Am Geriatr Soc. 2002;50(12):2014-2018.
296. Duthie SJ, Whalley LJ, Collins AR, Leaper S, Berger K, Deary IJ. Homocysteine, B vitamin status, and cognitive function in the elderly. Am J Clin Nutr. 2002;75(5):908-913.
297. Elias MF, Robbins MA, Budge MM, et al. Homocysteine and cognitive performance: modification by the ApoE genotype. Neurosci Lett. 2008;430(1):64-69.
298. Eussen SJ, Ueland PM, Clarke R, et al. The association of betaine, homocysteine and related metabolites with cognitive function in Dutch elderly people. Br J Nutr. 2007;98(5):960-968.
299. Garcia AA, Haron Y, Evans LR, Smith MG, Freedman M, Roman GC. Metabolic markers of cobalamin deficiency and cognitive function in normal older adults. J Am Geriatr Soc. 2004;52(1):66-71.
300. Hin H, Clarke R, Sherliker P, et al. Clinical relevance of low serum vitamin B12 concentrations in older people: the Banbury B12 study. Age Ageing. 2006;35(4):416-422.
301. Kado DM, Karlamangla AS, Huang MH, et al. Homocysteine versus the vitamins folate, B6, and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging. Am J Med. 2005;118(2):161-167.
302. Miller JW, Green R, Ramos MI, et al. Homocysteine and cognitive function in the Sacramento Area Latino Study on Aging. Am J Clin Nutr. 2003;78(3):441-447.
303. Morris MS, Jacques PF, Rosenberg IH, Selhub J. Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. Am J Clin Nutr. 2007;85(1):193-200.
304. Riggs KM, Spiro A, 3rd, Tucker K, Rush D. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr. 1996;63(3):306-314.
305. Styczynska M, Strosznajder JB, Religa D, et al. Association between genetic and environmental factors and the risk of Alzheimer's disease. Folia Neuropathol. 2008;46(4):249-254.
306. Wolters M, Hickstein M, Flintermann A, Tewes U, Hahn A. Cognitive performance in relation to vitamin status in healthy elderly German women-the effect of 6-month multivitamin supplementation. Prev Med. 2005;41(1):253-259.
307. Annerbo S, Wahlund LO, Lokk J. The relation between homocysteine levels and development of Alzheimer's disease in mild cognitive impairment patients. Dement Geriatr Cogn Disord. 2005;20(4):209-214.
308. Clarke R, Birks J, Nexo E, et al. Low vitamin B-12 status and risk of cognitive decline in older adults. Am J Clin Nutr. 2007;86(5):1384-1391.
309. Elias MF, Sullivan LM, D'Agostino RB, et al. Homocysteine and cognitive performance in the Framingham offspring study: age is important. Am J Epidemiol. 2005;162(7):644-653.
310. Gabryelewicz T, Styczynska M, Luczywek E, et al. The rate of conversion of mild cognitive impairment to dementia: predictive role of depression. Int J Geriatr Psychiatry. 2007;22(6):563-567.
311. Garcia A, Haron Y, Pulman K, Hua L, Freedman M. Increases in homocysteine are related to worsening of stroop scores in healthy elderly persons: a prospective follow-up study. J Gerontol A Biol Sci Med Sci. 2004;59(12):1323-1327.
312. Haan MN, Miller JW, Aiello AE, et al. Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: results from the Sacramento Area Latino Study on Aging. Am J Clin Nutr. 2007;85(2):511-517.
313. Kim JM, Stewart R, Kim SW, et al. Changes in folate, vitamin B12, and homocysteine associated with incident dementia. J Neurol Neurosurg Psychiatry. 2008;79(8):864-868.
314. Ravaglia G, Forti P, Maioli F, et al. Blood inflammatory markers and risk of dementia: The Conselice Study of Brain Aging. Neurobiol Aging. 2007;28(12):1810-1820.
315. Wright CB, Lee HS, Paik MC, Stabler SP, Allen RH, Sacco RL. Total homocysteine and cognition in a tri-ethnic cohort: the Northern Manhattan Study. Neurology. 2004;63(2):254-260.
316. Nurk E, Refsum H, Tell GS, et al. Plasma total homocysteine and memory in the elderly: the Hordaland Homocysteine Study. Ann Neurol. 2005;58(6):847-857.
317. Nurk E, Drevon CA, Refsum H, et al. Cognitive performance among the elderly and dietary fish intake: the Hordaland Health Study. Am J Clin Nutr. 2007;86(5):1470-1478.
318. McCaddon A, Hudson P, Davies G, Hughes A, Williams JH, Wilkinson C. Homocysteine and cognitive decline in healthy elderly. Dement Geriatr Cogn Disord. 2001;12(5):309-313.
319. Teunissen CE, Blom AH, Van Boxtel MP, et al. Homocysteine: a marker for cognitive performance? A longitudinal follow-up study. J Nutr Health Aging. 2003;7(3):153-159.
320. Oulhaj A, Refsum H, Beaumont H, et al. Homocysteine as a predictor of cognitive decline in Alzheimer's disease. Int J Geriatr Psychiatry. 2009 May 29. [Epub ahead of print].
321. Campbell AK, Jagust WJ, Mungas DM, et al. Low erythrocyte folate, but not plasma vitamin B-12 or homocysteine, is associated with dementia in elderly Latinos. J Nutr Health Aging. 2005;9(1):39-43.
322. Luchsinger JA, Tang MX, Shea S, Miller J, Green R, Mayeux R. Plasma homocysteine levels and risk of Alzheimer disease. Neurology. 2004;62(11):1972-1976.
323. Reitz C, Tang MX, Miller J, Green R, Luchsinger JA. Plasma homocysteine and risk of mild cognitive impairment. Dement Geriatr Cogn Disord. 2008;27(1):11-17.
324. Kalmijn S, Launer LJ, Lindemans J, Bots ML, Hofman A, Breteler MM. Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. Am J Epidemiol. 1999;150(3):283-289.
325. Mooijaart SP, Gussekloo J, Frolich M, et al. Homocysteine, vitamin B-12, and folic acid and the risk of cognitive decline in old age: the Leiden 85-Plus study. Am J Clin Nutr. 2005;82(4):866-871.
326. Clarke R, Harrison G, Richards S. Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia. J Intern Med. 2003;254(1):67-75.
327. Nilsson K, Gustafson L, Hultberg B. Plasma homocysteine concentration relates to the severity but not to the duration of Alzheimer's disease. Int J Geriatr Psychiatry. 2004;19(7):666-672.
328. Postiglione A, Milan G, Ruocco A, Gallotta G, Guiotto G, Di Minno G. Plasma folate, vitamin B(12), and total homocysteine and homozygosity for the C677T mutation of the 5,10-methylene tetrahydrofolate reductase gene in patients with Alzheimer's dementia. A case-control study. Gerontology. 2001;47(6):324-329.
329. Locascio JJ, Fukumoto H, Yap L, et al. Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol. 2008;65(6):776-785.
330. Corder EH, Beaumont H. Susceptibility groups for Alzheimer's disease (OPTIMA cohort): integration of gene variants and biochemical factors. Mech Ageing Dev. 2007;128(1):76-82.
331. Engelborghs S, Vloeberghs E, Maertens K, et al. Correlations between cognitive, behavioural and psychological findings and levels of vitamin B12 and folate in patients with dementia. Int J Geriatr Psychiatry. 2004;19(4):365-370.
332. Roos D, Willanger R. Various degrees of dementia in a selected group of gastrectomized patients with low serum B12. Acta Neurol Scand. 1977;55(5):363-376.
333. Wang HX, Wahlin A, Basun H, Fastbom J, Winblad B, Fratiglioni L. Vitamin B(12) and folate in relation to the development of Alzheimer's disease. Neurology. 2001;56(9):1188-1194.
334. Eussen SJ, Ferry M, Hininger I, Haller J, Matthys C, Dirren H. Five year changes in mental health and associations with vitamin B12/ folate status of elderly Europeans. J Nutr Health Aging. 2002;6(1): 43-50.
335. Garrod MG, Green R, Allen LH, et al. Fraction of total plasma vitamin B12 bound to transcobalamin correlates with cognitive function in elderly Latinos with depressive symptoms. Clin Chem. 2008;54(7):1210-1217.
336. Lopez OL, Becker JT, Klunk W, et al. Research evaluation and diagnosis of possible Alzheimer's disease over the last two decades: II. Neurology. 2000;55(12):1863-1869.
337. Luchsinger JA, Tang MX, Miller J, Green R, Mayeux R. Relation of higher folate intake to lower risk of Alzheimer disease in the elderly. Arch Neurol. 2007;64(1):86-92.
338. Small BJ, Viitanen M, Winblad B, Backman L. Cognitive changes in very old persons with dementia: the influence of demographic, psychometric, and biological variables. J Clin Exp Neuropsychol. 1997;19(2):245-260.
339. Small BJ, Backman L. Predictors of longitudinal changes in memory, visuospatial, and verbal functioning in very old demented adults. Dement Geriatr Cogn Disord. 1998;9(5):258-266.
340. Prodan CI, Cowan LD, Stoner JA, Ross ED. Cumulative incidence of vitamin B12 deficiency in patients with Alzheimer disease. J Neurol Sci. 2009;284(1-2):144-148.
341. American Academy of Neurology. Practice Parameter: Diagnosis of Dementia. American Academy of Neurology Guideline Summary for Clinicians. Detection, Diagnosis, and Management of Dementia: American Academy of Neurology. Current guideline-reaffirmed February 13, 2004. Available from: http://www.aan.com/ professionals/practice/pdfs/dementia_guideline.pdf. Accessed on September 7, 2009.
342. Valkovic P, Benetin J, Blazicek P, Valkovicova L, Gmitterova K, Kukumberg P. Reduced plasma homocysteine levels in levodopa/ entacapone treated Parkinson patients. Parkinsonism Relat Disord. 2005;11(4):253-256.
343. Postuma RB, Espay AJ, Zadikoff C, et al. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology. 2006;66(12):1941-1943.
344. Lamberti P, Zoccolella S, Iliceto G, et al. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Mov Disord. 2005;20(1):69-72.
345. Lamberti P, Zoccolella S, Armenise E, et al. Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration. Eur J Neurol. 2005;12(5):365-368.
346. Abyad A. Prevalence of vitamin B12 deficiency among demented patients and cognitive recovery with cobalamin replacement. J Nutr Health Aging. 2002;6(4):254-260.
347. Aisen PS, Schneider LS, Sano M, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008;300(15):1774-1783.
348. Balk EM, Raman G, Tatsioni A, Chung M, Lau J, Rosenberg IH. Vitamin B6, B12, and folic acid supplementation and cognitive function: a systematic review of randomized trials. Arch Intern Med. 2007;167(1):21-30.
349. Cunha UG. An investigation of dementia among elderly outpatients. Acta Psychiatr Scand. 1990;82(3):261-263.
350. Eastley R, Wilcock GK, Bucks RS. Vitamin B12 deficiency in dementia and cognitive impairment: the effects of treatment on neuropsychological function. Int J Geriatr Psychiatry. 2000;15(3):226-233.
351. Eussen SJ, de Groot LC, Joosten LW, et al. Effect of oral vitamin B12 with or without folic acid on cognitive function in older people with mild vitamin B12 deficiency: a randomized, placebo-controlled trial. Am J Clin Nutr. 2006;84(2):361-370.
352. Hvas AM, Juul S, Lauritzen L, Nexo E, Ellegaard J. No effect of vitamin B-12 treatment on cognitive function and depression: a randomized placebo controlled study. J Affect Disord. 2004;81(3):269-273.
353. Kwok T, Tang C, Woo J, Lai WK, Law LK, Pang CP. Randomized trial of the effect of supplementation on the cognitive function of older people with subnormal cobalamin levels. Int J Geriatr Psychiatry. 1998;13(9):611-616.
354. Lin YT, Lin MH, Lai HY, Chen LK, Hwang SJ, Lan CF. Regular vitamin B(12) supplementation among older Chinese men in a veterans care home in Taiwan. Arch Gerontol Geriatr. 2009;49(1): 186-189.
355. Malouf M, Grimley EJ, Areosa SA. Folic acid with or without vitamin B12 for cognition and dementia. Cochrane Database Syst Rev. 2003(4):CD004514.
356. Martin DC, Francis J, Protetch J, Huff FJ. Time dependency of cognitive recovery with cobalamin replacement: report of a pilot study. J Am Geriatr Soc. 1992;40(2):168-172.
357. McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med. 2006;354(26):2764-2772.
358. Nilsson K, Gustafson L, Hultberg B. Improvement of cognitive functions after cobalamin/folate supplementation in elderly patients with dementia and elevated plasma homocysteine. Int J Geriatr Psychiatry. 2001;16(6):609-614.
359. Osimani A, Berger A, Friedman J, Porat-Katz BS, Abarbanel JM. Neuropsychology of vitamin B12 deficiency in elderly dementia patients and control subjects. J Geriatr Psychiatry Neurol. 2005; 18(1):33-38.
360. Stott DJ, MacIntosh G, Lowe GD, et al. Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease. Am J Clin Nutr. 2005;82(6):1320-1326.
361. Sun Y, Lu CJ, Chien KL, Chen ST, Chen RC. Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients. Clin Ther. 2007;29(10):2204-2214.
362. van Dyck CH, Lyness JM, Rohrbaugh RM, Siegal AP. Cognitive and psychiatric effects of vitamin B12 replacement in dementia with low serum B12 levels: a nursing home study. Int Psychogeriatr. 2008:1-10.
363. van Uffelen JG, Chin APMJ, Hopman-Rock M, van Mechelen W. The effect of walking and vitamin B supplementation on quality of life in community-dwelling adults with mild cognitive impairment: a randomized, controlled trial. Qual Life Res. 2007;16(7):1137-1146.
364. van Uffelen JG, Chinapaw MJ, van Mechelen W, Hopman-Rock M. Walking or vitamin B for cognition in older adults with mild cognitive impairment? A randomised controlled trial. Br J Sports Med. 2008;42(5):344-351.
365. Ruscin JM, Page RL 2nd, Valuck RJ. Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor. Ann Pharmacother. 2002;36(5):812-816.
366. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol. 2004;57(4):422-428.
367. Mitchell SL, Rockwood K. The association between antiulcer medication and initiation of cobalamin replacement in older persons. J Clin Epidemiol. 2001;54(5):531-534.
368. Oh R, Brown DL. Vitamin B12 deficiency. Am Fam Physician. 2003;67(5):979-986.
369. Metz J. The deoxyuridine suppression test. Crit Rev Clin Lab Sci. 1984;20(3):205-241.
370. Allen RH, Stabler SP, Savage DG, Lindenbaum J. Diagnosis of cobalamin deficiency I: usefulness of serum methylmalonic acid and total homocysteine concentrations. Am J Hematol. 1990;34(2):90-98.
371. Clarke R, Sherliker P, Hin H, et al. Detection of vitamin B12 deficiency in older people by measuring vitamin B12 or the active fraction of vitamin B12, holotranscobalamin. Clin Chem. 2007;53(5): 963-970.
372. Herrmann W, Obeid R, Schorr H, Geisel J. Functional vitamin B12 deficiency and determination of holotranscobalamin in populations at risk. Clin Chem Lab Med. 2003;41(11):1478-1488.
373. Lindenbaum J, Savage DG, Stabler SP, Allen RH. Diagnosis of cobalamin deficiency: II. Relative sensitivities of serum cobalamin, methylmalonic acid, and total homocysteine concentrations. Am J Hematol. 1990;34(2):99-107.
374. Miller JW, Garrod MG, Rockwood AL, et al. Measurement of total vitamin B12 and holotranscobalamin, singly and in combination, in screening for metabolic vitamin B12 deficiency. Clin Chem. 2006;52(2):278-285.
375. Pennypacker LC, Allen RH, Kelly JP, et al. High prevalence of cobalamin deficiency in elderly outpatients. J Am Geriatr Soc. 1992;40(12): 1197-1204.
376. Smith DL. Anemia in the elderly. Am Fam Physician. 2000;62(7): 1565-1572.
377. Obeid R, Morkbak AL, Munz W, Nexo E, Herrmann W. The cobalaminbinding proteins transcobalamin and haptocorrin in maternal and cord blood sera at birth. Clin Chem. 2006;52(2):263-269.
378. Krasinski SD, Russell RM, Samloff IM, et al. Fundic atrophic gastritis in an elderly population. Effect on hemoglobin and several serum nutritional indicators. J Am Geriatr Soc. 1986;34(11):800-806.
379. Carmel R. Mild transcobalamin I (haptocorrin) deficiency and low serum cobalamin concentrations. Clin Chem. 2003;49(8):1367-1374.
380. Metz J, Bell AH, Flicker L, et al. The significance of subnormal serum vitamin B12 concentration in older people: a case control study. J Am Geriatr Soc. 1996;44(11):1355-1361.
381. Bor MV, Cetin M, Aytac S, Altay C, Nexo E. Nonradioactive vitamin B12 absorption test evaluated in controls and in patients with inherited malabsorption of vitamin B12. Clin Chem. 2005;51(11): 2151-2155.
382. McCaddon A, Hudson P, Abrahamsson L, Olofsson H, Regland B. Analogues, ageing and aberrant assimilation of vitamin B12 in Alzheimer's disease. Dement Geriatr Cogn Disord. 2001;12(2):133-137.
383. Refsum H, Smith AD. Low vitamin B12 status in conf irmed Alzheimer's disease as revealed by serum holotranscobalamin. J Neurol Neurosurg Psychiatry. 2003;74(7):959-961.
384. McCracken C, Hudson P, Ellis R, McCaddon A. Methylmalonic acid and cognitive function in the Medical Research Council Cognitive Function and Ageing Study. Am J Clin Nutr. 2006;84(6): 1406-1411.
385. Stabler SP, Allen RH, Savage DG, Lindenbaum J. Clinical spectrum and diagnosis of cobalamin deficiency. Blood. 1990;76(5): 871-881.
386. Zeitlin A, Frishman WH, Chang CJ. The association of vitamin b 12 and folate blood levels with mortality and cardiovascular morbidity incidence in the old old: the Bronx aging study. Am J Ther. 1997;4(7-8):275-281.
387. Dharmarajan TS, Norkus EP. Approaches to vitamin B12 deficiency. Early treatment may prevent devastating complications. Postgrad Med. 2001;110(1):99-105; quiz 106.
388. Hultberg B, Isaksson A, Nilsson K, Gustafson L. Homocysteine and methylmalonic acid as markers of cobalamin/folate status. The association to neuropsychiatric symptoms in the elderly is explored. Lakartidningen. 2000;97(38):4131-4134, 4136.
389. Nilsson K, Gustafson L, Hultberg B. Optimal use of markers for cobalamin and folate status in a psychogeriatric population. Int J Geriatr Psychiatry. 2002;17(10):919-925.
390. Savage DG, Lindenbaum J, Stabler SP, Allen RH. Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med. 1994;96(3):239-246.
391. Galimberti G, Conti E, Zini M, et al. Post-methionine load test: A more sensitive tool to reveal hyperhomocysteinemia in Alzheimer patients? Clin Biochem. 2008;41(10-11):914-916.
392. Kuzminski AM, Del Giacco EJ, Allen RH, Stabler SP, Lindenbaum J. Effective treatment of cobalamin deficiency with oral cobalamin. Blood. 1998;92(4):1191-1198.
393. Little DR. Ambulatory management of common forms of anemia. Am Fam Physician. 1999;59(6):1598-1604.
394. Hill DM, Johnson LJ, Burns PJ, Neale AM, Harmening DM, Kenney AC. Effects of temperature on stability of blood homocysteine in collection tubes containing 3-deazaadenosine. Clin Chem. 2002; 48(11):2017-2022.
395. Hansrani M, Stansby G. Extended storage of whole blood with 3-deazaadenosine for homocysteine assay. Ann Clin Biochem. 2007;44(Pt 4):388-390.
396. Joosten E, Pelemans W, Devos P, et al. Cobalamin absorption and serum homocysteine and methylmalonic acid in elderly subjects with low serum cobalamin. Eur J Haematol. 1993;51(1):25-30.
397. van Asselt DZ, Pasman JW, van Lier HJ, et al. Cobalamin supplementation improves cognitive and cerebral function in older, cobalamin-deficient persons. J Gerontol A Biol Sci Med Sci. 2001;56(12):M775-M779.
398. Annanmaki T, Pessala-Driver A, Hokkanen L, Murros K. Uric acid associates with cognition in Parkinson's disease. Parkinsonism Relat Disord. 2008;14(7):576-578.
399. Moretti R, Torre P, Antonello RM, Cazzato G, Cattaruzza T, Scapicchio PL. Vitamin B12 and folate depletion: clinical evidence in a neurological population. Neurologist. 2004;10(6):338-343.
400. Selhub J, Morris MS, Jacques PF. In vitamin B12 deficiency, higher serum folate is associated with increased total homocysteine and methylmalonic acid concentrations. Proc Natl Acad Sci U S A. 2007;104(50): 19995-20000.
401. Clarke R, Sherliker P, Hin H, et al. Folate and vitamin B12 status in relation to cognitive impairment and anaemia in the setting of voluntary fortification in the UK. Br J Nutr. 2008;100(5):1054-1059.
402. Santiesteban-Freixas R, Serrano-Verdura C, Gutierrez-Gil J, et al. The neuropathy epidemic in Cuba: eight years of investigation and follow-up. Rev Neurol. 2000;31(6):549-566.
403. Epidemic optic neuropathy in Cuba-clinical characterization and risk factors. The Cuba Neuropathy Field Investigation Team. N Engl J Med. 1995;333(18):1176-1182.
404. Dominguez YL, Hernandez M, Matos CM, Zhou D. Is B vitamins deficiency associated with prevalence of Alzheimer's disease in Cuban elderly? Nutr Health. 2006;18(2):103-118.
405. Hedges TR 3rd, Hirano M, Tucker K, Caballero B. Epidemic optic and peripheral neuropathy in Cuba: a unique geopolitical public health problem. Surv Ophthalmol. 1997;41(4):341-353.
406. Roman GC. An epidemic in Cuba of optic neuropathy, sensorineural deafness, peripheral sensory neuropathy and dorsolateral myeloneuropathy. J Neurol Sci. 1994;127(1):11-28.
407. Roman GC. On politics and health: an epidemic of neurologic disease in Cuba. Ann Intern Med. 1995;122(7):530-533.
408. Roman GC. Epidemic neuropathy in Cuba: a public health problem related to the Cuban Democracy Act of the United States. Neuroepidemiology. 1998;17(3):111-115.
409. Tucker K, Hedges TR. Food shortages and an epidemic of optic and peripheral neuropathy in Cuba. Nutr Rev. 1993;51(12):349-357.
410. The Flour Fortification Initiative. Countries with Mandatory Fortification of Flour with Iron and/or Folic Acid (Total //57). Available from: http://www.sph.emory.edu/wheatflour/COUNTRYDATA/ Mandatory_countries.pdf. Accessed on August 11, 2009.
411. Smithells RW, Sheppard S, Schorah CJ. Vitamin dificiencies and neural tube defects. Arch Dis Child. 1976;51(12):944-950.
412. Mills JL, McPartlin JM, Kirke PN, et al. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet. 1995;345(8943):149-151.
413. Bjorke-Monsen AL, Ueland PM, Schneede J, Vollset SE, Refsum H. Elevated plasma total homocysteine and C677T mutation of the methylenetetrahydrofolate reductase gene in patients with spina bifida. QJM. 1997;90(9):593-596.
414. Vollset SE, Refsum H, Irgens LM, et al. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study. Am J Clin Nutr. 2000;71(4): 962-968.
415. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med. 1992;327(26):1832-1835.
416. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet. 1991;338(8760):131-137.
417. Smithells RW, Sheppard S, Schorah CJ, et al. Possible prevention of neural-tube defects by periconceptional vitamin supplementation. Lancet. 1980;1(8164):339-340.
418. Laurence KM, James N, Miller MH, Tennant GB, Campbell H. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. Br Med J (Clin Res Ed). 1981;282(6275):1509-1511.
419. Czeizel AE. Prevention of congenital abnormalities by periconceptional multivitamin supplementation. BMJ. 1993;306(6893): 1645-1648.
420. Trends in wheat-flour fortification with folic acid and iron-worldwide, 2004 and 2007. MMWR Morb Mortal Wkly Rep. 2008;57(1):8-10.
421. Jacobsen DW. Homocysteine and vitamins in cardiovascular disease. Clin Chem. 1998;44(8 Pt 2):1833-1843.
422. Pitkin RM. Folate and neural tube defects. Am J Clin Nutr. 2007; 85(1):285S-288S.
423. Liu S, West R, Randell E, et al. A comprehensive evaluation of food fortification with folic acid for the primary prevention of neural tube defects. BMC Pregnancy Childbirth. 2004;4(1):20.
424. Lewis DP, Van Dyke DC, Stumbo PJ, Berg MJ. Drug and environmental factors associated with adverse pregnancy outcomes. Part III: Folic acid: pharmacology, therapeutic recommendations, and economics. Ann Pharmacother. 1998;32(10):1087-1095.
425. Leyva M. Folic acid intake and its effects on the prevention of neural tube defects, the masking of vitamin B12 deficiency and the reduction of homocysteine. J Okla State Med Assoc. 2002;95(5): 339-342.
426. Malinow MR, Duell PB, Hess DL, et al. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med. 1998;338(15): 1009-1015.
427. Kristensen MO, Gulmann NC, Christensen JE, Ostergaard K, Rasmussen K. Serum cobalamin and methylmalonic acid in Alzheimer dementia. Acta Neurol Scand. 1993;87(6):475-481.
428. Carmel R. Prevalence of undiagnosed pernicious anemia in the elderly. Arch Intern Med. 1996;156(10):1097-1100.
429. Kuroda S, Morita S. A case of pernicious anemia with type A gastritis in an extremely elderly patient with dementia and heart failure. Nippon Ronen Igakkai Zasshi. 2008;45(3):335-337.
430. Argyriadou S, Vlachonikolis I, Melisopoulou H, Katachanakis K, Lionis C. In what extent anemia coexists with cognitive impairment in elderly: a cross-sectional study in Greece. BMC Fam Pract. 2001;2:5.
431. McCaddon A, Kelly CL. Familial Alzheimer's disease and vitamin B12 deficiency. Age Ageing. 1994;23(4):334-337.
432. Nilsson K, Gustafson L, Faldt R, Andersson A, Hultberg B. Plasma homocysteine in relation to serum cobalamin and blood folate in a psychogeriatric population. Eur J Clin Invest. 1994;24(9):600-606.
433. McCaddon A, Tandy S, Hudson P, et al. Absence of macrocytic anaemia in Alzheimer's disease. Clin Lab Haematol. 2004;26(4): 259-263.
434. Gross JS, Weintraub NT, Neufeld RR, Libow LS. Pernicious anemia in the demented patient without anemia or macrocytosis. A case for early recognition. J Am Geriatr Soc. 1986;34(8):612-614.
435. Fox JH, Topel JL, Huckman MS. Dementia in the elderly-a search for treatable illnesses. J Gerontol. 1975;30(5):557-564.
436. Ikeda T, Furukawa Y, Mashimoto S, Takahashi K, Yamada M. Vitamin B12 levels in serum and cerebrospinal fluid of people with Alzheimer's disease. Acta Psychiatr Scand. 1990;82(4):327-329.
437. Kountouras J, Tsolaki M, Boziki M, et al. Association between Helicobacter pylori infection and mild cognitive impairment. Eur J Neurol. 2007;14(9):976-982.
438. Kountouras J, Boziki M, Gavalas E, et al. Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer's disease. J Neurol. 2009;256(5):758-767.
439. Malaguarnera M, Bella R, Alagona G, Ferri R, Carnemolla A, Pennisi G. Helicobacter pylori and Alzheimer's disease: a possible link. Eur J Intern Med. 2004;15(6):381-386.
440. Kountouras J, Tsolaki M, Gavalas E, et al. Relationship between Helicobacter pylori infection and Alzheimer disease. Neurology. 2006;66(6):938-940.
441. Vasconcellos LF, Correa RB, Chimelli L, et al. Myelopathy due to vitamin B12 deficiency presenting as transverse myelitis. Arq Neuropsiquiatr. 2002;60(1):150-154.
442. Gottfries J, Blennow K, Lehmann MW, Regland B, Gottfries CG. One-carbon metabolism and other biochemical correlates of cognitive impairment as visualized by principal component analysis. J Geriatr Psychiatry Neurol. 2001;14(3):109-114.
443. Faxen-Irving G, Basun H, Cederholm T. Nutritional and cognitive relationships and long-term mortality in patients with various dementia disorders. Age Ageing. 2005;34(2):136-141.
444. Jones S, Small BJ, Fratiglioni L, Backman L. Predictors of cognitive change from preclinical to clinical Alzheimer's disease. Brain Cogn. 2002;49(2):210-213.
445. McCaddon A, Kelly CL. Alzheimer's disease: a 'cobalaminergic' hypothesis. Med Hypotheses. 1992;37(3):161-165.
446. Opala G, Jasinska-Myga B, Ochudlo S, Janiec K. Diagnostic problems in the case of dementia with coexisting hematological disorders. Wiad Lek. 2001;54(7-8):456-461.
447. Carmel R, Ellenbogen L, Herbert VD. Dietary Supplement Fact Sheet Vitamin B12. Bethesda, MD: Office of Dietary Supplements, National Institutes of Health; 2006. Available from: From http://ods.od.nih.gov/ factsheets/VitaminB12_pf.asp. Accessed on January 18, 2009.
448. American Regent I. Cyanocobalamin Injection, USP. Package Insert. Shirley, NY: American Regent; 2003.
449. Braun-Falco O, Lincke H. The problem of vitamin B6/B12 acne. A contribution on acne medicamentosa (author's transl). MMW Munch Med Wochenschr. 1976;118(6):155-160.
450. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291(5): 565-575.
451. Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med. 2001;345(22):1593-1600.
452. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA. 2002;288(8):973-979.
453. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA. 2008;299(17):2027-2036.
454. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354(15):1578-1588.
455. Ebbing M, Bleie O, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA. 2008;300(7):795-804.
456. Lange H, Suryapranata H, De Luca G, et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med. 2004;350(26): 2673-2681.
457. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354(15): 1567-1577.
458. Mann JF, Sheridan P, McQueen MJ, et al. Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease-results of the renal Hope-2 study. Nephrol Dial Transplant. 2008;23(2):645-653.
459. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a metaanalysis of randomized controlled trials. JAMA. 2006;296(22): 2720-2726.
460. Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet. 2007;369(9576): 1876-1882.
461. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation. 1998;98(23):2520-2526.
462. Dangour AD, Breeze E, Clarke R, Shetty PS, Uauy R, Fletcher AE. Plasma homocysteine, but not folate or vitamin B-12, predicts mortality in older people in the United Kingdom. J Nutr. 2008;138(6): 1121-1128.
463. den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost. 1998;80(6):874-877.
464. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost. 2005;3(2):292-299.
465. Dhonukshe-Rutten RA, Pluijm SM, de Groot LC, Lips P, Smit JH, van Staveren WA. Homocysteine and vitamin B12 status relate to bone turnover markers, broadband ultrasound attenuation, and fractures in healthy elderly people. J Bone Miner Res. 2005;20(6): 921-929.
466. Kuo HK, Sorond FA, Chen JH, Hashmi A, Milberg WP, Lipsitz LA. The role of homocysteine in multisystem age-related problems: a systematic review. J Gerontol A Biol Sci Med Sci. 2005;60(9): 1190-1201.
467. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K. Homocysteine as a predictive factor for hip fracture in stroke patients. Bone. 2005;36(4):721-726.
468. Sato Y, Iwamoto J, Kanoko T, Satoh K. Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease. Am J Med. 2005;118(11):1250-1255.
469. Lehmann M, Regland B, Blennow K, Gottfries CG. Vitamin B12-B6-folate treatment improves blood-brain barrier function in patients with hyperhomocysteinaemia and mild cognitive impairment. Dement Geriatr Cogn Disord. 2003;16(3):145-150.
470. Flicker L, Martins RN, Thomas J, et al. B-vitamins reduce plasma levels of beta amyloid. Neurobiol Aging. 2008;29(2): 303-305.
471. Stuerenburg HJ, Mueller-Thomsen T, Methner A. Vitamin B12 plasma concentrations in Alzheimer disease. Neuro Endocrinol Lett. 2004;25(3):176-177.
472. La Rue A, Koehler KM, Wayne SJ, Chiulli SJ, Haaland KY, Garry PJ. Nutritional status and cognitive functioning in a normally aging sample: a 6-y reassessment. Am J Clin Nutr. 1997;65(1):20-29.
473. Bryan J, Calvaresi E, Hughes D. Short-term folate, vitamin B-12 or vitamin B-6 supplementation slightly affects memory performance but not mood in women of various ages. J Nutr. 2002;132(6): 1345-1356.
474. Remington R, Chan A, Paskavitz J, Shea TB. Efficacy of a vitamin/ nutriceutical formulation for moderate-stage to later-stage Alzheimer's disease: a placebo-controlled pilot study. Am J Alzheimers Dis Other Demen. 2009;24(1):27-33.
475. Ikeda T, Yamamoto K, Takahashi K, et al. Treatment of Alzheimer-type dementia with intravenous mecobalamin. Clin Ther. 1992;14(3): 426-437.
476. Alfthan G, Tapani K, Nissinen K, Saarela J, Aro A. The effect of low doses of betaine on plasma homocysteine in healthy volunteers. Br J Nutr. 2004;92(4):665-669.
477. Bell KM, Plon L, Bunney WE Jr, Potkin SG. S-adenosylmethionine treatment of depression: a controlled clinical trial. Am J Psychiatry. 1988;145(9):1110-1114.
478. Bottiglieri T. Ademetionine (S-adenosylmethionine) neuropharmacology: implications for drug therapies in psychiatric and neurological disorders. Expert Opin Investig Drugs. 1997;6(4):417-426.
479. Bressa GM. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl. 1994;154:7-14.
480. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood. 1997;90(1):1-11.
481. Di Rocco A, Rogers JD, Brown R, Werner P, Bottiglieri T. S-Adenosyl-Methionine improves depression in patients with Parkinson's disease in an open-label clinical trial. Mov Disord. 2000;15(6): 1225-1229.
482. Dudman NP, Guo XW, Gordon RB, Dawson PA, Wilcken DE. Human homocysteine catabolism: three major pathways and their relevance to development of arterial occlusive disease. J Nutr. 1996;126(4 Suppl):1295S-1300S.
483. Ho PI, Ashline D, Dhitavat S, et al. Folate deprivation induces neurodegeneration: roles of oxidative stress and increased homocysteine. Neurobiol Dis. 2003;14(1):32-42.
484. Jacob RA, Jenden DJ, Allman-Farinelli MA, Swendseid ME. Folate nutriture alters choline status of women and men fed low choline diets. J Nutr. 1999;129(3):712-717.
485. Kagan BL, Sultzer DL, Rosenlicht N, Gerner RH. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 1990;147(5):591-595.
486. Knopman D, Patterson M. An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients. Alzheimer Dis Assoc Disord. 2001;15(3):162-165.
487. Lipinski JF, Cohen BM, Frankenburg F, et al. Open trial of S-adenosylmethionine for treatment of depression. Am J Psychiatry. 1984;141(3):448-450.
488. McCaddon A. Homocysteine and cognitive impairment; a case series in a General Practice setting. Nutr J. 2006;5:6.
489. Melse-Boonstra A, Holm PI, Ueland PM, Olthof M, Clarke R, Verhoef P. Betaine concentration as a determinant of fasting total homocysteine concentrations and the effect of folic acid supplementation on betaine concentrations. Am J Clin Nutr. 2005;81(6):1378-1382.
490. Mitsuyama Y, Kogoh H. Serum and cerebrospinal fluid vitamin B12 levels in demented patients with CH3-B12 treatment-preliminary study. Jpn J Psychiatry Neurol. 1988;42(1):65-71.
491. Montero Brens C, Dalmau Serra J, Cabello Tomas ML, Garcia Gomez AM, Rodes Monegal M, Vilaseca Busca A. Homocystinuria: effectiveness of the treatment with pyridoxine, folic acid, and betaine. An Esp Pediatr. 1993;39(1):37-41.
492. Schwab U, Torronen A, Toppinen L, et al. Betaine supplementation decreases plasma homocysteine concentrations but does not affect body weight, body composition, or resting energy expenditure in human subjects. Am J Clin Nutr. 2002;76(5):961-967.
493. Selhub J, Bagley LC, Miller J, Rosenberg IH. B vitamins, homocysteine, and neurocognitive function in the elderly. Am J Clin Nutr. 2000;71(2):614S-620S.
494. Shippy RA, Mendez D, Jones K, Cergnul I, Karpiak SE. S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS. BMC Psychiatry. 2004;4:38.
495. Tavoni A, Jeracitano G, Cirigliano G. Evaluation of S-adenosylmethionine in secondary fibromyalgia: a double-blind study. Clin Exp Rheumatol. 1998;16(1):106-107.
496. Connelly PJ, Prentice NP, Cousland G, Bonham J. A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease. Int J Geriatr Psychiatry. 2008;23(2):155-160.
497. Ito T, Yamadera H, Ito R, Suzuki H, Asayama K, Endo S. Effects of vitamin B12 on bright light on cognitive and sleep-wake rhythm in Alzheimertype dementia. Psychiatry Clin Neurosci. 2001;55(3):281-282.
498. Haidemenos A, Kontis D, Gazi A, Kallai E, Allin M, Lucia B. Plasma homocysteine, folate and B12 in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(6):1289-1296.
499. King JC. Dietary Guidelines for Americans 2005. US Department of Health and Human Services and US Department of Agriculture. 2005. Available from: http://www.cnpp.usda.gov/Publications/ DietaryGuidelines/2005/2005DGPolicyDocument.pdf. Accessed on January 18, 2009.
500. Dierkes J, Domrose U, Ambrosch A, et al. Supplementation with vitamin B12 decreases homocysteine and methylmalonic acid but also serum folate in patients with end-stage renal disease. Metabolism. 1999;48(5):631-635.
501. Hoffer LJ, Saboohi F, Golden M, Barre PE. Cobalamin dose regimen for maximum homocysteine reduction in end-stage renal disease. Metabolism. 2005;54(6):835-840.
502. Eussen SJ, de Groot LC, Clarke R, et al. Oral cyanocobalamin supplementation in older people with vitamin B12 deficiency: a dose-finding trial. Arch Intern Med. 2005;165(10):1167-1172.
503. Nyholm E, Turpin P, Swain D, et al. Oral vitamin B12 can change our practice. Postgrad Med J. 2003;79(930):218-220.
504. Lederle FA. Oral cobalamin for pernicious anemia: back from the verge of extinction. J Am Geriatr Soc. 1998;46(9):1125-1127.
505. Kwong JC, Carr D, Dhalla IA, Tom-Kun D, Upshur RE. Oral vitamin B12 therapy in the primary care setting: a qualitative and quantitative study of patient perspectives. BMC Fam Pract. 2005;6(1):8.
506. Hengstermann S, Hanemann A, Nieczaj R, et al. Does an association between increased homocystein levels and cognitive dysfunction also exist in multimorbid geriatric patients? Z Gerontol Geriatr. 2009; 42(2):131-136.
507. Hengstermann S, Laemmler G, Hanemann A, et al. Total serum homocysteine levels do not identify cognitive dysfunction in multimorbid elderly patients. J Nutr Health Aging. 2008;12(6):411-416.
508. Huang YC, Kuo YW, Lee TH, et al. Hypoalbuminemia and not hyperhomocysteinemia as a risk factor for dementia in hemodialysis patients. J Ren Nutr. 2008;18(4):347-354.
509. Stipanuk MH, Dominy JE Jr, Lee JI, Coloso RM. Mammalian cysteine metabolism: new insights into regulation of cysteine metabolism. J Nutr. 2006;136(6 Suppl):1652S-1659S.
510. Fernandez HH, Wu CK, Ott BR. Pharmacotherapy of dementia with Lewy bodies. Expert Opin Pharmacother. 2003;4(11):2027-2037.
511. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebocontrolled international study. Lancet. 2000;356(9247):2031-2036.